TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04829162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother without obesity, daughter without obesity
Description: Participants in this group were shown an image of a mother without obesity and a daughter without obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother with obesity, son with obesity
Description: Participants in this group were shown an image of a mother with obesity and a son with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother with obesity, son without obesity
Description: Participants in this group were shown an image of a mother with obesity and a son without obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother without obesity, son with obesity
Description: Participants in this group were shown an image of a mother without obesity and a son with obesity.
Study: NCT01146457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Active dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline Control
Study: NCT00272662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study: NCT01331252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi-recumbent
Description: Patient rests in a semi-recumbent body position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supine
Description: Patient rests in a supine position
Study: NCT02720172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Home Exercise Program
Description: The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care involves standard postoperative management under the direction of the treating surgeon.
Study: NCT03124667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Games
Description: The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videos
Description: The video training will emphasize health and educational information.
Study: NCT03079713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld vibrator triggered during intravitreal injection for wet ARMD
Description: A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normal eye esthesiometry with and without vibration
Description: Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Handheld vibrator not triggered during intravitreal injection for wet ARMD
Description: Control group undergoing standard intravitreal injection without triggering of the vibrator.
Study: NCT02328378

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
Study: NCT00943449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-201
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-201
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: oral administration
Study: NCT04829162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother without obesity, son without obesity
Description: Participants in this group were shown an image of a mother without obesity and a son without obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father with obesity, daughter with obesity
Description: Participants in this group were shown an image of a father with obesity and a daughter with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father with obesity, daughter without obesity
Description: Participants in this group were shown an image of a father with obesity and a daughter without obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father without obesity, daughter with obesity
Description: Participants in this group were shown an image of a father without obesity and a daughter with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father without obesity, daughter without obesity
Description: Participants in this group were shown an image of a father without obesity and a daughter without obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father with obesity, son with obesity
Description: Participants in this group were shown an image of a father with obesity and a son with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father with obesity, son without obesity
Description: Participants in this group were shown an image of a father with obesity and a son without obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father without obesity, son with obesity
Description: Participants in this group were shown an image of a father without obesity and a son with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Father without obesity, son without obesity
Description: Participants in this group were shown an image of a father without obesity and a son without obesity.
Study: NCT02269540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: selective serotonin reuptake inhibitor
Study: NCT04334798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercises of the pelvic floor muscles & Electrostimulation & Biofeedback
Description: See information included in arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercises of the pelvic floor muscles & Biofeedback
Description: See information included in arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercises of the pelvic floor muscles & Transabdominal US Biofeedback
Description: See information included in arm/group descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active exercises of the pelvic floor muscles & Electrostimulation &Transabdominal US Biofeedback
Description: See information included in arm/group descriptions.
Study: NCT00004562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta adrenergic blockers
Description: Participants will receive beta adrenergic blockers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta adrenergic blockers
Description: Participants will receive beta adrenergic blockers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet inhibitors
Description: Participants will receive platelet inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet inhibitors
Description: Participants will receive platelet inhibitors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTCA and stents
Description: Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE Inhibitors
Description: Participants will receive ACE inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE Inhibitors
Description: Participants will receive ACE inhibitors.
Study: NCT03004820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
Study: NCT03010098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-Loop TCI
Description: the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-Loop TCI
Description: the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
Study: NCT04611789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3832479
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT02235662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV IVR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV IVR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TFV/LNG IVR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVR
Study: NCT04274114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L Glutamine
Description: Powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Powder
Study: NCT00999050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric bypass for diabetic patients <35 BMI
Description: The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
Study: NCT00914394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 1µg/kg/min, infusion period 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 1µg/kg/min, infusion period 20 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phenylephrine
Description: 1µg/kg/min, infusion period 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline solution (as placebo)
Description: infusion period 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline solution (as placebo)
Description: infusion period 20 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution (as placebo)
Description: infusion period 20 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: Measurements will be performed at the neuroretinal rim to assess ONH blood flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: Measurements will be performed at the neuroretinal rim to assess ONH blood flow.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: Measurements will be performed at the neuroretinal rim to assess ONH blood flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction cup
Description: Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction cup
Description: Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Suction cup
Description: Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
Study: NCT02269540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: selective serotonin reuptake inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: natural health product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: natural health product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: natural health product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Existing depression medication treatment
Description: Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
Study: NCT00512629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Omegaven is a fish based intravenous fat emulsion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Intralipid is a plant based intravenous fat emulsion
Study: NCT04085640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obturator nerve block with ropivacaine 0.2%.
Description: 20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Obturator nerve block with isotonic saline
Description: 20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
Study: NCT02380989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ayurveda
Description: Ayurveda combinations in the form of gel and patches were applied on acute pain site.
Study: NCT03929094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection（Albumin Bound）
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study: NCT01458093

Intervention type: OTHER
Intervention: colonoscopy
Description: evaluation of surveillance timing adequacy as compared to the guidelines
Study: NCT03647189

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hybrid Fractional Laser
Description: Hybrid Fractional Laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: Hybrid Fractional Laser
Study: NCT00930137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isocaloric for week diet
Description: Consumption of the 2 experimental diets~1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric for week diet
Description: Consumption of the 2 experimental diets~1. a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~2. a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal).
Study: NCT03827915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double sequential external defibrillation
Description: DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
Study: NCT01640431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
Study: NCT00108108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCD122
Study: NCT01429337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.
Study: NCT02431260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054329 Monotherapy
Description: Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
Study: NCT04204876

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnet Resonance Imaging (MRI)
Description: MRI with and without Gadolinium contrast agent for the following vessels: thoracic aorta (ascending, arch, descending arch, left and right common carotic, subclavian, and vertebral artery)

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT analysis
Description: Standard value uptake measurement (SUV) based on quantitative score normalized to liver (SUV vessel max/liver mean) at the following vessel regions: Carotid artery: common, internal, external; Subclavian artery; Axillary artery; Vertebral artery; Thoracic Aorta; Abdominal Aorta; Common femoral artery; Deep femoral artery; Popliteal artery
Study: NCT02227940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO
Study: NCT02380989

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01275586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasigna
Description: Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
Study: NCT02227940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01398917

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plastic endoprosthesis
Description: one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: balloon dilatation
Description: 4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)